Summary
Oncolytic virus therapy is a promising advancement in cancer immunotherapy, with four products approved globally, though production and quality control challenges remain. uBriGene's GMP production platform addresses these issues, providing scalable, cost-effective solutions and supporting an early-stage biotech company in advancing their Vaccinia Virus (VV) project through key stages, including process development, scale-up, and GMP production for IITs.
